Related Experiment Videos
Rate of visual field loss in progressive glaucoma
M T Rasker1, A van den Enden, D Bakker
1The Netherlands Ophthalmic Research Institute, and Glaucoma Department, Academic Medical Center, Amsterdam.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|April 15, 2000
Summary
The rate of visual field loss in normal-pressure glaucoma (NPG) and primary open-angle glaucoma (POAG) did not differ significantly. Progression of visual field loss was not linked to initial status or optic disc hemorrhages.
Area of Science:
- Ophthalmology
- Glaucoma Research
- Visual Field Analysis
Background:
- Glaucoma is a progressive optic neuropathy characterized by visual field (VF) loss.
- Understanding the rate of VF loss in different glaucoma subtypes is crucial for patient management.
- Normal-pressure glaucoma (NPG) and primary open-angle glaucoma (POAG) are common forms, with ocular hypertension (OHT) as a precursor.
Purpose of the Study:
- To investigate and compare the rate of visual field (VF) loss in patients with NPG and POAG.
- To determine if initial VF status or the presence of optic disc hemorrhages influences the rate of VF deterioration.
- To assess the applicability of linear regression in analyzing VF loss progression.
Main Methods:
- A cohort study followed 34 NPG, 68 POAG, and 125 OHT patients for approximately 9 years.
- Annual automated perimetry was used to obtain visual field data.
- The rate of VF loss was calculated as a percentage per year.
Main Results:
- The mean rates of VF deterioration were 3.7% per year in NPG and 2.5% per year in POAG, with no significant difference.
- No significant difference in VF loss rate was observed between eyes with and without optic disc hemorrhages.
- The rate of VF loss was not correlated with the initial VF status.
Conclusions:
- The rate of visual field loss is comparable between NPG and POAG.
- Progression of VF loss is not influenced by initial VF status or optic disc hemorrhages.
- Linear regression analysis for VF loss progression is only effective in a subset of patients.